2nd Quarter - Report

VIATRIS INC. for VIATRIS INC

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$265,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
2nd Quarter - Report (this page) Jul 20, 2016 $265,000 Replaced
2nd Quarter - Amendment Oct 20, 2016 $285,000 Yes

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

Trans Pacific Partnership(TPP), TTIP (trans-atlantic trade and investment partnership agreement); General trade issues

Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.

LobbyistCovered position, as disclosed
NAWEL LILLIAN ROJKJAER —
NIMISH SHAH —

Contacted: U.S. Trade Representative (USTR); Federal Trade Commission (FTC); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); SENATE; Program Support Center; White House Office

Budget/Appropriations BUD

Medicaid Generic Drug Rebate, Bipartisan Budget Act of 2015, H.R. 1314

Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.

LobbyistCovered position, as disclosed
NIMISH SHAH —

Contacted: Federal Trade Commission (FTC); Program Support Center; U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; SENATE; White House Office; Health & Human Services, Dept of (HHS)

Bills named: H.R. 1314 (114th)

Health Issues HCR

Biosimilar Naming, Implementation of Food and Drug Administration Safety and Innovation Act (FDASIA) and Generic Drug User Fee Act (GDUFA), PL 112-144 Prescription drug pricing, Medicare Part D program and Generic Drugs HR 6, 21st Century Cures Act; Innovation for Healthier Americans Initiative; Issues regarding market exclusivity Drug Supply Chain Security Act implementation of pharmaceutical distribution REMs program, S. 3056 CREATES Act, H.R. 2841 FAST generics Act S. 1972 Airline Access to Emergency Epinephrine Act of 2015, Anaphylaxis awareness, access to epinephrine auto injector; federal building anaphylaxis policy S. 2615 Increasing Competition in Pharmaceuticals Act, H.R. 4784 Lower Drug Costs through Competition Act, generic medicines pricing issues The Comprehensive Addiction and Recovery Act (CARA) S.524/H.R.953, the Addiction Prevention and Responsible Opioid Practices Act S.3075, Budgeting for CARA

Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.

LobbyistCovered position, as disclosed
MARC SCHLOSS —
NIMISH SHAH —

Contacted: Federal Trade Commission (FTC); SENATE; HOUSE OF REPRESENTATIVES; Program Support Center; U.S. Trade Representative (USTR); White House Office; Health & Human Services, Dept of (HHS)

Bills named: S. 3056 (114th), S. 2615 (114th), S. 1972 (114th), S. 524 (114th), H.R. 953 (114th), S. 3075 (114th), H.R. 2841 (114th), H.R. 4784 (114th), H.R. 6 (114th)

Foreign entities

Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.

EntityCountryPrincipal place of businessOwnershipContribution declared
MYLAN HOLDINGS LIMITED United Kingdom United Kingdom 100.0% —
MYLAN NV United Kingdom United Kingdom 100.0% —

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.